SynthesisAdvances in therapy2025

Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison.

Koo Wilson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.